Principal Owner
Melinta Therapeutics is an antibiotics-focused company that develops and commercializes antibiotics to overcome drug-resistant infections.
Highly skilled Clinical Microbiologist with expertise in both discovery research and clinical development of new antibiotics. Key contributor to three recent antibiotic FDA approvals including delafloxacin (Baxdela), dalbavancin (Dalvance) and ceftolozane/tazobactam (Zerbaxa) Specialties: Clinical Microbiology; Regulatory Writing, Editing and Publishing including New Drug Applications (NDA), Drug Safety Update Reports (DSUR), Investigator Brochures (IB), FDA responses including briefing books and SPA agreements, Non-Clinical Study Reports, Abstracts, Posters, Manuscripts and Grants.
Anymail finder is trusted by tens of thousands of companies to provide accurate contact information to their Sales and Business Development teams.
If you're looking to find the email of Sandra Mccurdy at Melinta Therapeutics then you've come to the right place.
Wondering if it's sandra@melinta.com, sandra.mccurdy@melinta.com, mccurdy@melinta.com, or smccurdy@melinta.com? We have the answers for you.